Caerin 1.1 and 1.9 peptides halt B16 melanoma metastatic tumours via expanding cDC1 and reprogramming tumour macrophages
Our findings suggest that caerin 1.1 and 1.9, combined with immunotherapy, effectively modulate the tumour microenvironment in primary and secondary tumours, leading to reduced tumour growth and enhanced systemic immunity. Further investigation into these mechanisms could pave the way for improved combination therapies in advanced melanoma treatment.
Authors
- Tianfang Wang (ORCID: https://orcid.org/0000-0002-4876-7767)
- Guoying Ni (ORCID: https://orcid.org/0000-0002-7410-5900)
- Junjie Li (ORCID: https://orcid.org/0000-0002-5397-084X)
- Zhu Chen (ORCID: https://orcid.org/0000-0002-6162-885X)
- Xiaosong Liu (ORCID: https://orcid.org/0000-0001-9577-7725)
- Hejie Li (ORCID: https://orcid.org/0000-0002-1135-5478)
- Quanlan Fu
- Yuandong Luo
Institutions
- University of the Sunshine Coast (AU)
- Guizhou University (CN)
- Guangdong Pharmaceutical University (CN)
- Guizhou Cancer Hospital (CN)
- First People's Hospital of Foshan (CN)
- First Affiliated Hospital of Guangdong Pharmaceutical University (CN)
- Zhongshan Hospital (CN)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2024-10-28
- DOI
- https://doi.org/10.1186/s12967-024-05763-x
- Citations
- 7
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 1.68
Funders
- National Science Foundation
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province
- Guangdong Pharmaceutical University